#######################
# Document Properties #
#######################
SET DOCUMENT Copyright   = "Copyright © 2019 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Licenses    = "CC BY 4.0"
SET DOCUMENT ContactInfo = "charles.hoyt@scai.fraunhofer.de"

SET DOCUMENT Name        = "Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis."
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Yojana Gadiya"
SET DOCUMENT Description = ""

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
 DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/chebi-names.belns"
# DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/drugbank-names.belns"
# DEFINE NAMESPACE DOID           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c0c576e3d3ab9b25a3982251a4ee2fd7c49e1679/external/doid-names.belns"
# DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ec-code.belns"
# DEFINE NAMESPACE FB             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/fb-names.belns"
 DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc-names.belns"
 DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hgnc.genefamily-names.belns"
# DEFINE NAMESPACE HP             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/hp-names.belns"
 DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/go-names.belns"
 DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/interpro-names.belns"
 DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mesh-names.belns"
# DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns"
# DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
# DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/ncbigene.belns"
# DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/pfam-names.belns"
# DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
 DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
 DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
 DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
 DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
 DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------
DEFINE ANNOTATION Species       AS PATTERN "^\d+$"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
 DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
 DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
 DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
 DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
 DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
 DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
 DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
 DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
 DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
 DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
 DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############
SET Citation = {"PubMed", "30837838"}

SET Evidence = "TAR DNA binding protein-43 (TDP-43) was identified in 1995 as a repressor protein associated with HIV-1 transcription, which binds to the trans-active response element DNA sequence of the viral genome and is critical for the regulation of the viral gene expression (Ou et al., 1995)."
p(HGNC:"TARDBP") -- path(MESH:"HIV-1")
p(HGNC:"TARDBP") reg path(MESH:"Gene Expression Regulation, Viral")

SET Evidence = "In 2001, TDP-43 was also reported to be involved in RNA splicing of cystic fibrosis transmembrane conductance regulator (CFTR) exons (Buratti and Baralle, 2001)."
act(p(HGNC:"TARDBP"), ma(MESH:"RNA Splicing")) -- p(HGNC:"CFTR")

SET Evidence = "TDP- 43 has since then been also shown to regulate mRNAs involved in the development of neurons and embryos (Polymenidou et al., 2011; Sephton et al., 2011; Tollervey et al., 2011)."
p(HGNC:"TARDBP") -- path(MESH:"Embryonic Development")
p(HGNC:"TARDBP") -- bp(GO:"neuron development")

SET Evidence = "In 2006, TDP-43 was identified as a key component of the insoluble and ubiquitinated inclusions in the brains of patients suffering from amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD or FTLD-TDP) diseases (Arai et al., 2006; Neumann et al., 2006)."
SET MeSHAnatomy = "Brain"
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"TARDBP", pmod("Ub"))
path(MESH:"Frontotemporal Lobar Degeneration") -- p(HGNC:"TARDBP", pmod("Ub"))
UNSET MeSHAnatomy

SET Evidence = "Other diseases
involving TDP-43 pathological developments are primary lateral
sclerosis and progressive muscular atrophy, and together these
four diseases are known as TDP-proteinopathies (Figure 1)
(Dugger and Dickson, 2017)."
#Muscular Atrophy, Spinal : progressive muscular atrophy
path(MESH:"Motor Neuron Disease") -- p(HGNC:"TARDBP")
path(MESH:"Muscular Atrophy, Spinal") -- p(HGNC:"TARDBP")

SET Evidence = "In addition to the TDP-43 encoding TARDBP gene,mutations
in several other genes have also been linked with ALS such
as: SOD1 (Superoxide dismutase 1) (Rosen, 1993; Kunst et al.,
1997), FUS (Fused in sarcoma) (Kwiatkowski et al., 2009; Vance
et al., 2009), C9ORF72 (Hexanucleotide repeat expansion in
C9ORF72) (Dejesus-Hernandez et al., 2011; Renton et al., 2011),
ATXN2 (Ataxin-2) (Elden et al., 2010; Ross et al., 2011), OPTN
(Optineurin) (Maruyama et al., 2010), VCP (Valosin-containing
protein) (Johnson et al., 2010; Koppers et al., 2012), PFN1
(Profilin 1) (Wu et al., 2012; Tanaka et al., 2016), UBQLN2 and
UBQLN4 (Ubiquilin 2 and Ubiquilin 4) (Deng et al., 2011; Edens
et al., 2017), NEK1 (NIMA-like kinase 1) (Brenner et al., 2016),
MATR3 (Matrin 3) (Johnson et al., 2014b), CHCHD10 (Coiledcoil-
helix-coiled-coil-helix domain containing 10) (Woo et al.,
2017), SETX (Senataxin) (Hirano et al., 2011), TBK1 (TANKbinding
kinase 1) (Oakes et al., 2017), and KIF5A (Kinesin heavy
chain isoform 5A) (Nicolas et al., 2018) etc."
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"SOD1")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"FUS")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"C9orf72")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"ATXN2")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"OPTN")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"VCP")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"PFN1")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"UBQLN2")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"UBQLN4")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"NEK1")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"MATR3")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"CHCHD10")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"SETX")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"TBK1")
path(MESH:"Amyotrophic Lateral Sclerosis") -- p(HGNC:"KIF5A")

SET Evidence = "TDP-43 inclusions in FTLD-TDP are also hyper-phosphorylated,
ubiquitinated and N-terminally truncated as observed in ALS
(Neumann et al., 2007a; Hasegawa et al., 2008; Igaz et al., 2008)."
#N-terminally truncated : aa 1-102
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", pmod(Ub))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", pmod(Ph))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", frag("1","102"))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", pmod(Ub))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", pmod(Ph))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", frag("1","102"))

SET Evidence = "Also, mutations in the TARDBP gene can lead to ALS as well as
the FTLD-TDP disease."
p(HGNC:"TARDBP", var("?")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("?")) -> path(MESH:"Frontotemporal Lobar Degeneration")

SET Evidence = "In ALS, there is an increase in the cytoplasmic TDP-
43 concentration leading to cytoplasmic inclusion formation
(Neumann et al., 2006; Winton et al., 2008a)."
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", loc(MESH:"Cytoplasm")) -> path(MESH:"Inclusion Bodies")
UNSET MeSHDisease

SET Evidence = "TDP-43’s dimerization apparently occurs through
interactions of the N-terminal residues and while several reports
suggest that TDP-43 N-terminal domain’s (NTD) dimerization
is necessary for its physiological functions like RNA splicing."
#head - to -head N-terminal interactions
complex(p(HGNC:"TARDBP", frag("1","102")),p(HGNC:"TARDBP", frag("1","102"))) -> path(MESH:"RNA Splicing")

SET Evidence = "Others have also argued that the NTD’s dimerization may, in
fact, be involved in its aggregation (Shiina et al., 2010; Zhang
Y. J. et al., 2013; Afroz et al., 2017)."
complex(p(HGNC:"TARDBP", frag("1","102")),p(HGNC:"TARDBP", frag("1","102"))) -- path(MESH:"Protein Aggregation, Pathological")

SET Evidence = "Indeed, the dimeric TDP-43 NTD has been shown
to enhance its pre-mRNA splicing activity, improve solubility
and protect against the formation of the cytoplasmic TDP-
43 inclusions (Jiang et al., 2017)."
complex(p(HGNC:"TARDBP", frag("1","102")),p(HGNC:"TARDBP", frag("1","102"))) -> path(MESH:"RNA Splicing")
complex(p(HGNC:"TARDBP", frag("1","102")),p(HGNC:"TARDBP", frag("1","102"))) -> path(MESH:"Solubility")
complex(p(HGNC:"TARDBP", frag("1","102")),p(HGNC:"TARDBP", frag("1","102"))) -| path(MESH:"Inclusion Bodies")

SET Evidence = "Deletion
or mutation in the nuclear localization signal (NLS) sequence
in the NTD induces cytoplasmic relocalization and aggregation
of TDP-43 (Winton et al., 2008a; Barmada et al., 2010)."
#NLS : aa 82 - 98
p(HGNC:"TARDBP", frag("82","98"), var("?")) -> p(HGNC:"TARDBP", frag("1","102"), loc(MESH:"Cytoplasm"))
p(HGNC:"TARDBP", frag("82","98"), var("?")) ->p(HBP:"TDP-43 aggregates")

SET Evidence = "In
fact, the ALS-associated A90V mutation present in the nuclear
localization signal (NLS) can sequester the endogenous TDP-43
into insoluble cytoplasmic aggregates (Winton et al., 2008b)."
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", frag("82","98"), var("p.Ala90Val")) -> p(HGNC:"TARDBP". pmod("Protein Aggregates"),loc(MESH:"Cytoplasm"))
UNSET MeSHDisease

SET Evidence = "These proteins are involved in several RNA
metabolic processes like mRNA processing, RNA export and
RNA stability."
#These proteins - RNA binding proteins
p(MESH:"RNA-Binding Proteins") -- path(MESH:"RNA Stability")
p(MESH:"RNA-Binding Proteins") -- bp(GO:"mRNA processing")
p(MESH:"RNA-Binding Proteins") -- path(MESH:"RNA Transport")

SET Evidence = "Several mutations in the RRMs are shown to disrupt
the RNA binding capability while not significantly interfering
with the RNA recognition (Lukavsky et al., 2013)."
#RRM1 (aa 104–176) and RRM2 (aa 192–262)
p(HGNC:"TARDBP", frag("104","176"), var("?")) -| bp(GO:"RNA binding")
p(HGNC:"TARDBP", frag("192","262"), var("?")) -| bp(GO:"RNA binding")
p(HGNC:"TARDBP", frag("104","176"), var("?")) cnc path(MESH:"RNA Recognition Motif")
p(HGNC:"TARDBP", frag("192","262"), var("?")) cnc path(MESH:"RNA Recognition Motif")

SET Evidence = "Notably,
two ALS-linked missense mutations have also been identified
in this region: the P112H and the caspase cleavage susceptible,
D169G (Buratti, 2015; Moreno et al., 2015; Chiang et al., 2016)."
p(HGNC:"TARDBP", frag("104","176"), var("p.Pro112His")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", frag("192","262"), var("p.Asp169Gly")) -> path(MESH:"Amyotrophic Lateral Sclerosis")

SET Evidence = "Proposedly, the RRM2 domain may also contribute to the
dimerization of the TDP-43 protein (Kuo et al., 2009)."
p(HGNC:"TARDBP", frag("192","262")) -> complex(p(HGNC:"TARDBP", frag("1","102")),p(HGNC:"TARDBP", frag("1","102")))

SET Evidence = "Binding to
single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA),
and not to double-stranded DNA (dsDNA), has been shown to
enhance the TDP-43’s solubility and expectedly also prevent its
aggregation (Huang et al., 2013; Sun and Chakrabartty, 2017)."
composite(p(HGNC:"TARDBP", frag("192","262")), p(MESH:"DNA, Single-Stranded")) -> path(MESH:"Solubility")
composite(p(HGNC:"TARDBP", frag("192","262")), p(MESH:"DNA, Single-Stranded")) -|p(HBP:"TDP-43 aggregates")

SET Evidence = "Importantly, TDP-43 actively binds to the 3′ untranslated regions
(UTRs) of several thousand mRNA transcripts, and even to
its own mRNA as an autoregulation mechanism to control
its own cellular concentration and possibly also its solubility
(Ayala et al., 2011)."
composite(p(HGNC:"TARDBP", frag("192","262")),p(MESH:"3' Untranslated Regions")) reg  path(MESH:"Solubility")
composite(p(HGNC:"TARDBP", frag("192","262")),p(MESH:"3' Untranslated Regions")) reg path(MESH:"Homeostasis")

SET Evidence = "Thirdly, certain C-terminal fragments of sizes ∼25–35 kDa
produced from TDP-43 through aberrant activity of caspases,
are highly cytotoxic and are the prominent species found in
the inclusion bodies identified from the ALS-affected brains
(Zhang et al., 2007, 2009)."
#C-terminal domain - aa 274-414
p(HGNC:"TARDBP", frag("274","414")) -- path(MESH:"Cytotoxins")
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
SET MeSHAnatomy = "Brain"
p(HGNC:"TARDBP", frag("274","414")) -- path(MESH:"Inclusion Bodies")
UNSET MeSHAnatomy
UNSET MeSHDisease

SET Evidence = "TDP-43 has versatile functions and it is involved in several
steps of RNA metabolism such as: transcription, translation,
mRNA transport, mRNA stabilization, microRNA (miRNA) and
long non-coding RNA (lncRNA) processing etc. (Ling et al.,
2013; Coyne et al., 2017) (Figure 3)."
#Protein Biosynthesis : translation
#Active Transport, Cell Nucleus : Nucleo-cytoplasmic shuttling
p(HGNC:"TARDBP") -- path(MESH:"RNA Stability")
p(HGNC:"TARDBP") -- path(MESH:"Transcription, Genetic")
p(HGNC:"TARDBP") -- path(MESH:"Protein Biosynthesis")
p(HGNC:"TARDBP") -- bp(GO:"primary miRNA processing")
p(HGNC:"TARDBP") -- path(MESH:"RNA, Long Noncoding")
p(HGNC:"TARDBP") -- path(MESH:"RNA Transport")
p(HGNC:"TARDBP") -- path(MESH:"Active Transport, Cell Nucleus")
p(HGNC:"TARDBP") -- a(GO:"cytoplasmic stress granule")

###Question - TDP-43 and TARDBP
SET Evidence = "It regulates the splicing patterns of transcripts of
several important genes, such as Cystic fibrosis transmembrane
conductance regulator (CFTR), TARDBP, FUS, SNCA (a-
synuclein), HTT (Huntingtin), and APP (Amyloid precursor
protein) etc."
#It - TDP-43
p(HGNC:"TARDBP") reg p(HGNC:"CFTR")
p(HGNC:"TARDBP") reg p(HGNC:"FUS")
p(HGNC:"TARDBP") reg p(HGNC:"SNCA")
p(HGNC:"TARDBP") reg p(HGNC:"HTT")
p(HGNC:"TARDBP") reg p(HGNC:"APP")

SET Evidence = "In fact, nuclear depletion of TDP-43 results in
mRNA splicing aberrations (Arnold et al., 2013; Highley et al.,
2014; Yang et al., 2014)."
p(HGNC:"TARDBP") reg path(MESH:"RNA Splicing")

SET Evidence = "Indeed, imbalances caused by
the overexpression of TDP-43 are detrimental to the neuronal
cells (Cannon et al., 2012; Heyburn and Moussa, 2016; Lu
et al., 2016)."
p(HGNC:"TARDBP") neg p(MESH:"Neurons")

SET Evidence = "Two ALS-associated
mutations in TDP-43, Q331K, and M337V, have also been shown
to alter mRNA splicing processes in a transgenic mice model
(Polymenidou et al., 2011, 2012; Lagier-Tourenne et al., 2012;
Arnold et al., 2013)."
SET Species = "10090"
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", var("p.Gln133Arg")) -- path(MESH:"RNA Splicing")
p(HGNC:"TARDBP", var("p.Met337Val")) -- path(MESH:"RNA Splicing")
UNSET MeSHDisease
UNSET Species

SET Evidence = "TDP-43 associates with the RNA molecules to produce
ribonucleoprotein (RNP) granules which transport mRNA to
distant locations."
complex(p(HGNC:"TARDBP"), p(MESH:"RNA")) -> p(MESH:"Ribonucleoproteins")
p(MESH:"Ribonucleoproteins") -> path(MESH:"RNA Transport")

SET Evidence = "In fact, ALS-associated TDP-43 mutants were found to impair the
transportation of the RNP granules (Wang et al., 2008; Alami
et al., 2014)."
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", var("?")) -| path(MESH:"RNA Transport")
UNSET MeSHDisease

SET Evidence = "Several of these interactions were unperturbed by the ALS-linked
mutations, A315T and M337V (Freibaum et al., 2010; Kim et al.,
2010)."
#These interaction : RNA splicing and translation
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", var("p.Ala315Thr")) cnc path(MESH:"RNA Splicing")
p(HGNC:"TARDBP", var("p.Ala315Thr")) cnc path(MESH:"Translations")
p(HGNC:"TARDBP", var("p.Met337Val")) cnc path(MESH:"RNA Splicing")
p(HGNC:"TARDBP", var("p.Met337Val")) cnc path(MESH:"Translations")
UNSET MeSHDisease

SET Evidence = "Recent studies in Drosophila, have reported that TDP-43
regulates localization and translation of the Futsch (ortholog of
Map1b) mRNA at the neuromuscular junctions (Coyne et al.,
2014)."
#5740544 : Futsch
SET Species = "7215"
SET CellStructure = "Neuromuscular Junction"
p(HGNC:"TARDBP") reg p(NCBIGENE:"5740544")
UNSET CellStructure
UNSET Species

SET Evidence = "In one study, an increase in cytoplasmic TDP-43 caused
repression of the global protein synthesis in the neuroblastoma
cells, which could be rescued by the over-expression of RACK1
(Russo et al., 2017)."
#TDP-43 and RACK1 form complex
SET MeSHDisease = "Neuroblastoma"
p(HGNC:"TARDBP") -| path(MESH:"Protein Biosynthesis")
complex(p(HGNC:"TARDBP"), p(HGNC:"RACK1")) -> path(MESH:"Protein Biosynthesis")
UNSET MeSHDisease

SET Evidence = "In fact, TDP-43 is involved in
both assembly and maintenance of SGs, and it also regulates the
expression of key SG nucleating proteins, rasGAP SH3 domain
binding protein 1 (G3BP) and T cell-restricted intracellular
antigen-1 (TIA-1) (McDonald et al., 2011)."
p(HGNC:"TARDBP") reg a(GO:"cytoplasmic stress granule")
p(HGNC:"TARDBP") reg p(HGNC:"G3BP1")
p(HGNC:"TARDBP") reg p(HGNC:"TIA1")

###How to code?
SET Evidence = "Under sorbitol-induced
osmotic stress, the G348C mutant TDP-43 was found to be
localized into progressively larger stress granules (Dewey et al.,
2011)."

SET Evidence = "On the contrary, the R361S mutant of TDP-43 was shown
to disrupt the stress granule assembly (McDonald et al., 2011)."
p(HGNC:"TARDBP", var("p.Arg361Ser")) -| a(GO:"cytoplasmic stress granule")

SET Evidence = "TDP-43 also promotes biogenesis and processing of the noncoding
RNAs, such as microRNA (miRNA) (Kawahara and
Mieda-Sato, 2012)."
p(HGNC:"TARDBP") -> p(MESH:"MicroRNAs")

SET Evidence = "TDP-
43 associates with the nuclear Drosha complex and binds
directly to the primary miRNAs to facilitate the production
of a subset of precursor miRNAs (pre-miRNAs) (Kawahara
and Mieda-Sato, 2012)."
complex(p(HGNC:"TARDBP"), p(HGNC:"DROSHA"), p(MESH:"MicroRNAs")) -> p(GO:"pre-miRNA processing")

SET Evidence = "In human embryonic kidney 293 cells (HEK293), it is found that the cytoplasmic TDP-43
interacts with the Dicer complex and promotes pre-miRNA
processing (Kawahara and Mieda-Sato, 2012). "
SET CellLine = "HEK293"
complex(p(HGNC:"TARDBP"), p(HGNC:"DICER1")) -> p(GO:"pre-miRNA processing")
UNSET CellLine

SET Evidence = "Interestingly, NEAT1 and
MALAT1 are also found at elevated levels in FTLD-TDP
(Tollervey et al., 2011)."
SET MeSHDisease = "Frontotemporal Lobar Degeneration"
p(HGNC:"TARDBP") -> p(HGNC:"NEAT1")
p(HGNC:"TARDBP") -> p(HGNC:"MALAT1")
UNSET MeSHDisease

###Proteinpathoies?
###Localization?
SET Evidence = "The pathological hallmarks of TDP-43 proteinopathies
include nucleus to cytoplasmic mislocalization, deposition
of ubiquitinated and hyper-phosphorylated TDP-43 into
inclusion bodies, protein truncation leading to formation of
toxic C-terminal TDP-43 fragments, and protein aggregation."
p(HGNC:"TARDBP") -| p(HGNC:"TARDBP", pmod("Ph"), loc(GO:"inclusion body"))
p(HGNC:"TARDBP") -| p(HGNC:"TARDBP", pmod("Ub"), loc(GO:"inclusion body"))
p(HGNC:"TARDBP") -| path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP") -| path(MESH:"Peptide Fragments")

SET Evidence = "The effects of these mutations on
the TDP-43 protein include: increased propensity to aggregate,
enhanced cytoplasmic mislocalization, altered protein stability,
resistance to proteases or modified binding interactions with
other proteins etc."
#These mutations : Related to ALS and FTLD
SET MeSHDisease = {"Frontotemporal Lobar Degeneration", "Amyotrophic Lateral Sclerosis"}
p(HGNC:"TARDBP", var("?")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("?")) neg bp(GO:"regulation of cytoplasmic transport")
p(HGNC:"TARDBP", var("?")) -| path(MESH:"Protein Stability")
p(HGNC:"TARDBP", var("?")) -| path(MESH:"Proteolysis")
p(HGNC:"TARDBP", var("?")) -| path(MESH:"Protein Binding")
UNSET MeSHDisease

SET Evidence = "Most of the ALS associated
mutations appear in the exon 6 of the TARDBP gene which encodes for the C-terminal glycine-rich region of
TDP-43."
#Gly rich domain - 366-414aa
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", frag("336","414"))

SET Evidence = "The most commonly occurring missense mutations
are A382T and M337V and some of the most well-studied
mutations are A315T, Q331K, M337V, D169G, G294A/V, and
Q343R etc., for which several ALS-disease models have also
been established (Buratti, 2015)."
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Ala382Thr"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Met337Val"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Ala315Thr"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Gln331Lys"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Met337Val"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Asp169Gly"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Gly294Ala"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Gly294Val"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Gln343Arg"))


###fALS and sporadic ALS
SET Evidence = "DP-43 mutations including
A90V and N267S are observed in both cases of sporadic
ALS as well as FTLD whereas R361T was reported in a patient case of fALS and FTLD."
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Ala90Val"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Asn267Ser"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Arg361Thr"))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", var("p.Ala90Val"))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", var("p.Asn267Ser"))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", var("p.Arg361Thr"))

SET Evidence = "Mutations, such as G294V,
G348C, A328T, and S393L are found in both the sporadic as
well as familial cases of ALS."
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Gly348Cys"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Ala328Thr"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Ser393Leu"))

SET Evidence = "Interestingly, TDP-43 mutation
G295S encompasses various pathological conditions including
sALS, fALS, and FTLD (Baumer et al., 2009; Xiong et al.,
2010; Fujita et al., 2011; Janssens et al., 2011; Budini et al.,
2012; Chiang et al., 2012; Cruts et al., 2012; Lattante et al.,
2013; Moreno et al., 2015)."
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", var("p.Gly295Ser"))
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", var("p.Gly295Ser"))

SET Evidence = "Of interest, a fALS associated
phosphorylation-prone TDP-43 mutant, which contains G298S
mutation in the mitochondrial localizing internal motif M5,
was found to have increased import into the mitochondria
(Wang et al., 2016)."
SET MeSHDisease = "Frontotemporal Lobar Degeneration"
p(HGNC:"TARDBP", var("p.Gly295Ser"), loc(GO:"mitochondrion")) -> bp(GO:"protein import into mitochondrial matrix")
UNSET MeSHDisease

SET Evidence = "Mutations in the TDP-43’s C-terminal region enhance
its intrinsic aggregation propensity (Johnson et al., 2009)."
#C-terminal - 274-414aa
p(HGNC:"TARDBP", frag("274", "414")) -> path(MESH:"Protein Aggregation, Pathological")

SET Evidence = "Recombinantly expressed TDP-43 protein harboring the ALSlinked
mutations, such as Q331K, M337V, Q343R, N345K,
R361S, and N390D, were found to have increased aggregation
in vitro and also promoted cytotoxicity in the yeast cells
(Johnson et al., 2009)."
SET Species = "4932"
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", var("p.Gln331Lys")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Gln331Lys")) -> path(MESH:"Cytotoxicity, Immunologic")
p(HGNC:"TARDBP", var("p.Met337Val")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Met337Val")) -> path(MESH:"Cytotoxicity, Immunologic")
p(HGNC:"TARDBP", var("p.Arg361Ser")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Arg361Ser")) -> path(MESH:"Cytotoxicity, Immunologic")
p(HGNC:"TARDBP", var("p.Gln343Arg")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Gln343Arg")) -> path(MESH:"Cytotoxicity, Immunologic")
p(HGNC:"TARDBP", var("p.Asn345Lys")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Asn345Lys")) -> path(MESH:"Cytotoxicity, Immunologic")
p(HGNC:"TARDBP", var("p.Asn390Asp")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Asn390Asp")) -> path(MESH:"Cytotoxicity, Immunologic")
UNSET MeSHDisease
UNSET Species

SET Evidence = "Peptides from the TDP-43’s putative
amyloidogenic core region (aa 286–366) containing the ALS associated mutations
were also found to efficiently form amyloid like
fibrils (Chen et al., 2010; Guo et al., 2011; Sun et al.,
2011; Zhu et al., 2014) (Table 2)."
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", frag("286", "366"), var("?")) -> path(MESH:"Amyloid")
UNSET MeSHDisease

SET Evidence = "Interestingly, Zhu et al.
have reported that an aggregated TDP-43 peptide with the
A315E mutation is capable even of cross-seeding the aggregation
of the amyloid-b 1–40 peptide (Zhu et al., 2014)."
p(HGNC:"TARDBP", var("p.Ala315Glu"), loc(HBP:"TDP-43 aggregates")) -> p(HGNC:"APP", frag("1", "40"), loc(HBP:"amyloid-beta aggregates"))

SET Evidence = "Also,
Guo et al. have shown that TDP-43 A315T forms amyloid
fibrils in vitro and causes neuronal death when added to the
cultured neuronal cells (Guo et al., 2011)."
p(HGNC:"TARDBP", var("p.Ala315Thr")) -> path(MESH:"Amyloid")
p(HGNC:"TARDBP", var("p.Ala315Thr")) -> bp(GO:"neuron death")

SET Evidence = "Certain mutations
in TDP-43 like G294V, A315T, M337V, A382T, and G376D,
are also found to enhance the cytoplasmic mislocalization
of TDP-43 (Barmada et al., 2010; Mutihac et al., 2015;
Mitsuzawa et al., 2018)."
p(HGNC:"TARDBP", var("p.Gly294Val")) neg bp(GO:"regulation of cytoplasmic transport")
p(HGNC:"TARDBP", var("p.Ala315Thr")) neg bp(GO:"regulation of cytoplasmic transport")
p(HGNC:"TARDBP", var("p.Met337Val")) neg bp(GO:"regulation of cytoplasmic transport")
p(HGNC:"TARDBP", var("Ala382Thr")) neg bp(GO:"regulation of cytoplasmic transport")
p(HGNC:"TARDBP", var("Gly376Asp")) neg bp(GO:"regulation of cytoplasmic transport")


###Granule erminology NAMESPACE??
SET Evidence = "Additionally, the aggregation-enhancing A315T and Q343R
mutations have been shown to increase TDP-43-containing RNA
granule’s average sizes, decrease their distribution density and
also hamper their mobility in the neuronal cells (Liu-Yesucevitz
et al., 2014)."
p(HGNC:"TARDBP", var("p.Ala315Thr")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Gln343Arg")) -> path(MESH:"Protein Aggregation, Pathological")

SET Evidence = "The mutations, D169G, G294A, Q343R, N390D,
Q331K, and M337V, were found to enhance the formation of
TDP-43-positive inclusion bodies in the neuronal cell line, SHSY5Y
(Nonaka et al., 2009a)."
#CellLine : SHSY5Y
p(HGNC:"TARDBP", var("p.Asp169Gly")) -> path(MESH:"Inclusion Bodies")
p(HGNC:"TARDBP", var("p.Gly294Ala")) -> path(MESH:"Inclusion Bodies")
p(HGNC:"TARDBP", var("p.Gln343Arg")) -> path(MESH:"Inclusion Bodies")
p(HGNC:"TARDBP", var("p.Asn390Asp")) -> path(MESH:"Inclusion Bodies")
p(HGNC:"TARDBP", var("p.Gln331Lys")) -> path(MESH:"Inclusion Bodies")
p(HGNC:"TARDBP", var("p.Met337Val")) -> path(MESH:"Inclusion Bodies")

SET Evidence = "In one
study, the ALS-linked TDP-43 with the mutations G298S,
Q331K, and M337V, showed longer half-life and higher
stability than the wild-type TDP-43 (half-life: ∼24–48 h vs.
12 h for the wild-type TDP-43) in an isogenic cell line (Ling
et al., 2010)."
#isogenic cell line
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"TARDBP", var("p.Gln331Lys")) -> path(MESH:"Protein Stability")
p(HGNC:"TARDBP", var("p.Gly298Ser")) -> path(MESH:"Protein Stability")
p(HGNC:"TARDBP", var("p.Met337Val")) -> path(MESH:"Protein Stability")
UNSET MeSHDisease

SET Evidence = "Further evidence from the works of Watanabe
et al. (2013) and Austin et al. (2014), has shown that the
accelerated disease onset in the familial ALS patients is related
to the TDP-43 mutations (such as: A315T, Q343R, N352S,
M337V, G298S, G348C, A382T, D169G, and K263E) possibly
via increase in the protein half-lives and the aggregation
propensities, which may further influence their own mRNA’s
processing and cause misregulation of the TDP-43’s translation
(Watanabe et al., 2013; Austin et al., 2014)."
p(HGNC:"TARDBP", var("p.Ala315Thr")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Gln343Arg")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Asn352Ser")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Met337Val")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Gly298Ser")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Gly348Cys")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Ala382Thr")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Asp169Gly")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Arg263Glu")) -> path(MESH:"Amyotrophic Lateral Sclerosis")
p(HGNC:"TARDBP", var("p.Ala315Thr")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Gln343Arg")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Asn352Ser")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Met337Val")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Gly298Ser")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Gly348Cys")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Ala382Thr")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Asp169Gly")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Arg263Glu")) -> path(MESH:"Protein Aggregation, Pathological")
p(HGNC:"TARDBP", var("p.Ala315Thr")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Gln343Arg")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Asn352Ser")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Met337Val")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Gly298Ser")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Gly348Cys")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Ala382Thr")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Asp169Gly")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Arg263Glu")) reg bp(GO:"mRNA processing")
p(HGNC:"TARDBP", var("p.Ala315Thr")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Gln343Arg")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Asn352Ser")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Met337Val")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Gly298Ser")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Gly348Cys")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Ala382Thr")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Asp169Gly")) neg bp(GO:"translation")
p(HGNC:"TARDBP", var("p.Arg263Glu")) neg bp(GO:"translation")

SET Evidence = "Calpain-I could fragment the recombinant TDP-43 A315T and
M337V mutant proteins more rapidly than the wild-type TDP-
43, whereas the D169G mutant TDP-43 was more efficiently
cleaved by caspase-3 in vitro (Yamashita et al., 2012; Chiang
et al., 2016)."
p(HGNC:"CAPN1") -> p(HGNC:"TARDBP", var("p.Ala315Thr"), frag("?"))
p(HGNC:"CAPN1") -> p(HGNC:"TARDBP", var("p.Met337Val"), frag("?"))
p(HGNC:"CASP3") -> p(HGNC:"TARDBP", var("p.Asp169Gly"), frag("?"))

SET Evidence = "Interestingly, another mutation A90V in TDP-
43 imparts partial resistance to the digestion by caspase-3
(Wobst et al., 2017)."
p(HGNC:"CASP3") -| p(HGNC:"TARDBP", var("p.Ala90Val"), frag("?"))

SET Evidence = "One of the prominent features of ALS and FTLD-TDP, is the
loss of functional TDP-43 in the nucleus and its increased
deposition into cytoplasmic inclusion bodies in the brain and
spinal cord neurons (Arai et al., 2006; Neumann et al., 2006)."
path(MESH:"Frontotemporal Lobar Degeneration") neg act(p(HGNC:"TARDBP", loc(GO:"nucleus")))
path(MESH:"Amyotrophic Lateral Sclerosis") neg act(p(HGNC:"TARDBP", loc(GO:"nucleus")))
SET MeSHAnatomy = {"Brain", "Spinal Cord"}
SET CellStructure = "Cytoplasm"
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", loc(GO:"inclusion body"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", loc(GO:"inclusion body"))
UNSET CellStructure
UNSET MeSHAnatomy

SET Evidence = "It is accepted that
the cytoplasmic accumulation and the aggregation of TDP-43
into inclusion bodies confer both a loss-of-function as well as
a gain-of-toxic-function (Vanden Broeck et al., 2015; Ederle
and Dormann, 2017)."
SET CellStructure = "Inclusion Bodies"
p(HGNC:"TARDBP", loc(GO:"cytoplasm")) -| act(p(HGNC:"TARDBP"))
p(HGNC:"TARDBP", loc(HBP:"TDP-43 aggregates")) -| act(p(HGNC:"TARDBP"))
p(HGNC:"TARDBP", loc(GO:"cytoplasm")) -> path(MESH:"Toxic Actions")
p(HGNC:"TARDBP", loc(HBP:"TDP-43 aggregates")) -> path(MESH:"Toxic Actions")
UNSET CellStructure

SET Evidence = "The cytoplasmic
accumulation into inclusion bodies reduces the amount of
TDP-43 necessary for mRNA transport."
p(HGNC:"TARDBP", loc(MESH:"Inclusion Bodies")) -| p(HGNC:"TARDBP", ma(MESH:"RNA Transport"))

SET Evidence = "Recently, TDP-43 has
also been found to function as a translational repressor by
interacting with the ribosomal protein, receptor of activated
protein C kinase 1 (RACK1), thereby resulting in the global
protein synthesis inhibition (Russo et al., 2017)."
complex(p(HGNC:"TARDBP"), p(HGNC:"RACK1")) -| path(MESH:"Protein Biosynthesis")

SET Evidence = "RACK1 was also found to be sequestered into the TDP-43
inclusions in the motor neurons of the ALS patients (Russo et al.,
2017)."
SET Cell = "motor neuron"
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"RACK1") -> (p(HGNC:"TARDBP", loc(GO:"inclusion body"))
UNSET MeSHDisease
UNSET Cell

SET Evidence = "Deletion of the nuclear localization signal (NLS) [or nuclear
export signal (NES)] sequence impairs TDP-43’s functions."
deg(p(MESH:"Nuclear Localization Signals")) -| act(p(HGNC:"TARDBP"))
deg(p(MESH:"Nuclear Export Signals")) -| act(p(HGNC:"TARDBP"))


###TDP-43 with del NLS how to code???
SET Evidence = "Expectedly, TDP-43 with the nuclear localization signal (NLS)
deletion accumulates as cytoplasmic aggregates and can
even sequester the native TDP-43 thereby further depleting
the TDP-43 pool, which consequently alters the transcripts
that regulate chromatin assembly and histone processing
(Winton et al., 2008a; Amlie-Wolf et al., 2015)."

###???
SET Evidence = "TDP-43 mutant with nuclear export signal (NES) deletion
manifested a propensity to form nuclear aggregates (Winton
et al., 2008a)."

###CK2 namespace?
SET Evidence = "The
casein kinases, CK1 and CK2, have been shown to mediate
phosphorylations at Ser-379, Ser-403, Ser-404, and especially
Ser-409/Ser-410, which are now considered a signature
of ALS pathology (Neumann et al., 2006, 2009)."
SET MeSHDisease = "Amyotrophic Lateral Sclerosis"
p(HGNC:"CSNK1A1") -> p(HGNC:"TARDBP", pmod(Ph, Ser, 379))
p(HGNC:"CSNK1A1") -> p(HGNC:"TARDBP", pmod(Ph, Ser, 403))
p(HGNC:"CSNK1A1") -> p(HGNC:"TARDBP", pmod(Ph, Ser, 404))
p(HGNC:"CSNK1A1") -> p(HGNC:"TARDBP", pmod(Ph, Ser, 409))
p(HGNC:"CSNK1A1") -> p(HGNC:"TARDBP", pmod(Ph, Ser, 410))
UNSET MeSHDisease

SET Evidence = "Another
kinase, glycogen synthase kinase (GSK3) is also found to be
involved in the TDP-43’s phosphorylation (Sreedharan et al.,
2015)."
#GSK3 : GSK3A
p(HGNC:"GSK3A") -- p(HGNC:"TARDBP", pmod("Ph"))

SET Evidence = "The TDP-43’s phosphorylation is associated with its
increased cytoplasmic mislocalization and aggregation in the
neuronal cells (Nonaka et al., 2009a, 2016; Barmada et al.,
2010; Liachko et al., 2010; Choksi et al., 2014)."
SET Cell = "neuron"
p(HGNC:"TARDBP", pmod("Ph")) -> p(HGNC:"TARDBP", pmod("Protein Aggregates"))
UNSET Cell

SET Evidence = "While affected brain cortex shows
accumulation of phosphorylated C-terminal fragments, the
spinal-cord cells show a predominant deposition of the
phosphorylated full-length TDP-43 (Neumann et al., 2009)."
#Affected with ALS and FTLD
#C-terminal domain - aa 274-414
SET MeSHAnatomy = "Neocortex"
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", frag("274", "414"), pmod("Ph"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", frag("274", "414"), pmod("Ph"))
UNSET MeSHAnatomy
SET MeSHAnatomy = "Cord"
path(MESH:"Frontotemporal Lobar Degeneration") -> p(HGNC:"TARDBP", pmod("Ph"))
path(MESH:"Amyotrophic Lateral Sclerosis") -> p(HGNC:"TARDBP", pmod("Ph"))
UNSET MeSHAnatomy

SET Evidence = "The E3 ubiquitin ligase (Parkin) is shown to ubiquitinate TDP-43
via the ubiquitin lysines, K-48, and K-63."
p(HGNC:"PRKN") ->  p(HGNC:"TARDBP", pmod("Ub", Lys, 48))
p(HGNC:"PRKN") ->  p(HGNC:"TARDBP", pmod("Ub", Lys, 63))

SET Evidence = "The ubiquitin-conjugating enzyme
UBE2E3 and ubiquitin-isopeptidase Y (UBPY) were identified,
in a yeast two-hybrid screen, to interact with TDP-43 and
this interaction is proposed to enhance the ubiquitination and
accumulation of its insoluble high molecular weight aggregates
(Hans et al., 2014)."
complex(p(HGNC:"UBE2E3"), p(HGNC:"TARDBP")) -> p(HGNC:"TARDBP", pmod("Ub"))
complex(p(HGNC:"UBE2E3"), p(HGNC:"TARDBP")) -> p(HGNC:"TARDBP", pmod("Protein Aggregates"))
complex(p(HGNC:"USP8"), p(HGNC:"TARDBP")) -> p(HGNC:"TARDBP", pmod("Ub"))
complex(p(HGNC:"USP8"), p(HGNC:"TARDBP")) -> p(HGNC:"TARDBP", pmod("Protein Aggregates"))

SET Evidence = "Notably, an FTLD-associated TDP-43 with
K263E mutation was observed to be excessively ubiquitinated,
possibly as a consequence of its misfolding due to the substitution
of the positively charged lysine residue with a negatively charged
aspartate residue in the RRM2 domain (Hans et al., 2014)."
SET MeSHDisease = "Frontotemporal Lobar Degeneration"
p(HGNC:"TARDBP", var("p.Lys293Asp")) -> p(HGNC:"TARDBP", pmod("Ub"))
UNSET MeSHDisease

SET Evidence = "TDP-43 aggregates are labeled by both K-48- and K-63-linked
polyubiquitin chains and subsequently directed toward different
fates: ubiquitin proteasomal-mediated degradation of TDP-43 for
the K-48-linked polyubiquitin chains, and autophagic removal of
the TDP-43 with K-63-linked polyubiquitin chains (Scotter et al.,
2014)."
p(HGNC:"TARDBP", pmod("Ub", Lys, 48)) -> bp(GO:"proteasome-mediated ubiquitin-dependent protein catabolic process")
p(HGNC:"TARDBP", pmod("Ub", Lys, 63)) -> path(MESH:"Autophagy")

SET Evidence = "Moreover, mutations at these ubiquitination sites were also
found to decrease the TDP-43’s accumulation thereby implicating
the ubiquitination in modulating the TDP-43 aggregation
(Dammer et al., 2012)."
#These ubiquitination - K-48, K-63
p(HGNC:"TARDBP", pmod("Ub", Lys, 48), var("?")) -| p(HGNC:"TARDBP", pmod("Protein Aggregates"))
p(HGNC:"TARDBP", pmod("Ub", Lys, 63), var("?")) -| p(HGNC:"TARDBP", pmod("Protein Aggregates"))


###mutated but location unknow how to code?
SET Evidence = "Using an acetylation mimic, where
lysine was mutated to glutamine residue, the TDP-43 acetylation
was shown to impair RNA binding, disturb mitochondrial
functions, and promote accumulation of the insoluble and hyperphosphorylated
TDP-43 aggregates in the neuronal cell cultures
(Cohen et al., 2015)."
SET Cell = "neuron"
p(HGNC:"TARDBP", pmod("Ac")) -> p(HGNC:"TARDBP", pmod("Ph"))
p(HGNC:"TARDBP", pmod("Ac")) -| p(GO:"RNA binding")
p(HGNC:"TARDBP", pmod("Ac")) -> path(HBP:"mitochondrial dysfunction")
UNSET Cell

SET Evidence = "In another study, arsenite-induced oxidative
stress could trigger the TDP-43’s acetylation and formation of
aggregates of ∼75–250 kDa (Cohen et al., 2015; Wang P. et al.,
2017)."
a(CHEBI:"arsenite ion") -> path(MESH:"Oxidative Stress")
path(MESH:"Oxidative Stress") -> p(HGNC:"TARDBP", pmod("Ac"))
path(MESH:"Oxidative Stress") -> p(HGNC:"TARDBP", pmod("Protein Aggregates"))

SET Evidence = "The PARP enzyme, tankyrase,
was shown to reduce the TDP-43’s aggregation by non-covalently
attaching PAR via PAR-binding motif present in the TDP-43
nuclear localization signal (NLS) sequence."
#NLS of TARDBP : 82-98aa
p(HGNC:"TNKS") -> complex(a(CHEBI:"cyclic ADP-ribose"), p(HGNC:"TARDBP", frag("82", "98")))
complex(a(CHEBI:"cyclic ADP-ribose")), p(HGNC:"TARDBP", frag("82", "98"))) -| p(HGNC:"TARDBP", pmod("Protein Aggregates"))

SET Evidence = ""
